Q-omics provides the consensus-scored CAB39L profile across patient tissues and cancer cell-line models. CAB39L expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CAB39L is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, CAB39L protein abundance shows 29,725 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, HNSC, and GBM as cancer lineages where CAB39L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CAB39L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CAB39L survival associations across molecular data types. CAB39L RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CAB39L RNA expression–survival associations across cancer types. High CAB39L expression shows unfavorable associations in OV, UVM and CESC, but favorable associations in KIRC, MESO and ACC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CAB39L RNA expression.
This table summarizes CAB39L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 8. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CAB39L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CAB39L shows lower tumor expression in HNSC, KIRC, THCA, KICH, LUAD and KIRP. The HNSC box plot shows higher CAB39L RNA expression in normal versus tumor tissue (log2 FC = −1.559, t-test p < 0.001).
This table shows molecular features associated with CAB39L in patient tissues and cancer cell lines. In patient samples, CAB39L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CAB39L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and CNS.
